Trial Profile
A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Calcitriol (Primary) ; Peginterferon alfa; Ribavirin; Vitamin D analogues
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms Addwin
- 02 Mar 2023 Status changed from not yet recruiting to completed.
- 22 Sep 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01439776, ML25569).
- 22 Sep 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.